🏠
📞  +353 1 6643768
 
📧  info@medaval.ie
Ascensia Contour Next Link (Bayer)
Device Name:
Contour Next Link
Manufacturer:
Bayer Healthcare AG, Kaiser-Willhelm-Allee, Building W11, 51368 Leverkusen, GERMANY.
Measuring functions:
Blood glucose
Primary Client Use:
Intended for both professional use and self-measurement
Measurement Site:
Finger and general Alternative Site Testing
Measurement Occurrence:
Single measurements only
Availability:
Available Currently
Availability according to Countries or Regions:
Ireland and United States
Device Manual:
Description:
The Ascensia Contour Next Link (Bayer) is an automatic blood glucose meter. The accuracy of its blood glucose measurement technology has yet to be proven to MDR requirements. Blood glucose measurements are normally taken from the finger but alternative site testing is allowed. It is intended for both professional use and self-measurement.
Assessment:
While the technology used in the Ascensia Contour Next Link (Bayer), to measure blood glucose, has been assessed, the results of the study have not been published and cannot be verified.
Recommendations:
Accuracy AssessmentRecommendationBasis
BG Medaval None While a clinical validation is claimed, it cannot be checked properly.
BG Institute of Health Economics (CA) General use No evidence provided
Relevant Publications:

Greene C, Brown D, Wallace JF, Pardo S, Pflug B. Comparative Accuracy of 3 Blood Glucose Monitoring Systems that Communicate with an Insulin Pump. Endocr Pract. 2014 Oct;20(10):1016-21. doi: 10.4158/EP13484.OR. PMID: 24793918.

Measurements from the Ascensia (Bayer) Contour Next Link are compared to those from the J&J OneTouch UltraLink and the Nova Max Link, though not in a formal validation.

Massa GG, Gys I, Op't Eyndt A, Bevilacqua E, Wijnands A, Declercq P, Zeevaert R. Evaluation of the FreeStyle® Libre Flash Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes. Horm Res Paediatr. 2018;89(3):189-99. Epub: 2018 Mar 27. doi: 10.1159/000487361. PMID: 29587254.

Comparison in children and adolescents with T1DM (aged 4 to 18 years) (along with the Roche Accu-Chek Mobile and the JnJ LifeScan OneTouch Verio IQ) to the Abbott FreeStyle Libre Flash (n=26). Authors conclude reasonable agreement but with large interindividual variability and that further studies in children are imperative.